Roche ended 2019 on a subtle note, with erosion of key off-patent drugs capping gains from new high-potential drugs like Ocrevus, Hemlibra and Tecentriq. Nevertheless, full-year sales growth was 9% CER vs. early-2019 guidance of low-to-mid single-digit growth. While the group’s pipeline – especially in oncology, remains impressive, relatively muted 2020 guidance (vs. Novartis) is an indication of the biosimilar impact eventually gathering momentum.
11 Feb 2020
Good 2019, despite ‘relatively’ sluggish Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good 2019, despite ‘relatively’ sluggish Q4
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
11 Feb 2020 -
Author:
Surbhit Gupta -
Pages:
5
Roche ended 2019 on a subtle note, with erosion of key off-patent drugs capping gains from new high-potential drugs like Ocrevus, Hemlibra and Tecentriq. Nevertheless, full-year sales growth was 9% CER vs. early-2019 guidance of low-to-mid single-digit growth. While the group’s pipeline – especially in oncology, remains impressive, relatively muted 2020 guidance (vs. Novartis) is an indication of the biosimilar impact eventually gathering momentum.